|Title|Presenting author|Presentation|
|Cabotegravir for Pre-exposure prophylaxis (PrEP)|
|PILLAR month 12 clinical results: zero HIV acquisition and high persistence with CAB LA for PrEP|T. Khan|Oral Abstract 196
12 March 2025
10:00 AM PT|
|Performance of HIV RNA screening in the context of long-acting injectable cabotegravir in HPTN 084|S. Delany-Moretlwe|Oral Abstract 195
12 March 2025
10:00 AM PT|
|ImPrEP CAB Brasil: Enhancing PrEP Coverage with CAB-LA in Young Key Populations|B. Grinsztejn|Oral Abstract 192
12 March 2025
10:00 AM PT|
|Estimation of prevention-effective CAB-LA concentrations among MSM/TGW in HPTN 083|B. Hanscom|Oral Abstract 193
12 March 2025
10:00 AM PT|
|Response to HIV Treatment After Long-Acting Cabotegravir Pre-exposure Prophylaxis in HPTN 083|R. Landovitz|Oral Abstract 197
12 March 2025
10:00 AM PT|
|No increased risk for hypertension with CAB-LA compared to TDF/FTC for PrEP: results from HPTN 084|S. Delany-Moretlwe|Poster 820|
|High incidence of curable sexually transmitted infections in HPTN 084: a tertiary analysis|H. Nuwagaba-Biribonwoha|Poster 1226|
|PrEP choices among sexual and gender minorities in Brazil: the ImPrEP CAB-LA study|B. Grinsztejn|Poster 1356|
|Depression and suicide risk among sexual and gender minorities: insights from the ImPrEP CAB Brazil|D. Richer Araujo Coelho|Poster 1302|
|Patterns of first choice, switching, and discontinuation of oral and injectable PrEP among adolescents from sexual and gender minorities in Brazil|L. Magno Santos de Sousa|Poster 1203|
|Acceptability of long-acting cabotegravir among pregnant and lactating people in South Africa|N. Wara|Poster 1357|
|Impact of rapid long-acting prep scale-up among MSM: closing the unmet needs and towards ending HIV|H. Wang|Poster 1297|
|Expanding the PrEP method market: Early insights from offering oral PrEP, PrEP ring, and injectable CAB PrEP for HIV prevention across five countries in Africa|N. Naidoo|Poster 1354|
|Dynamic choice HIV prevention in the context of injectable cabotegravir (CAB-LA): a model-based cost-effectiveness analysis|M. Hickey|Poster 1293|
|Use of DNA profiling to resolve discrepant HIV tests in the setting of injectable cabotegravir PrEP|J. Fogel|Poster 1193|
|Cabotegravir for Treatment|
|Randomized trial of cabotegravir and rilpivirine long-acting in Africa (CARES): week 96 results|C. Kityo|Oral Abstract 202
12 March 2025
12:15 PM PT|
|Long-term CAB+RPV LA effectiveness in virologically suppressed individuals in the OPERA cohort|M. Sension|Poster 674|
|Clinical outcomes among virologically suppressed women receiving CAB+RPV LA in the OPERA cohort|J. Altamirano|Poster 676|
|Outcomes on cabotegravir + rilpivirine in suppressed people with HIV (PWH) in TRIO health US cohort|P. Sax|Poster 675|
|Decreasing oral induction duration in support of LAI ART use with hard-to-reach populations|A. Rana|Poster 692|
|At home CAB/RPV provides novel approach to achieve viral suppression in adherence challenged PWH|M. Dieterich|Poster 1318|
|Safety and pharmacokinetics of long-acting cabotegravir and rilpivirine in children between 20-40kgs|M. Archary|Poster 1046|
|Interim Week 48 results in South African youth living with HIV on long-acting injectable therapy: AFINAty study|L. Jennings|Poster 679|
|Pipeline|
|Proof-of-concept trial of VH4524184 (VH-184), a third-generation integrase strand transfer inhibitor|L. Rogg|Oral Abstract 152
11 March 2025
10:13-10:21 PT|
|Proof-of-concept trial of oral VH4011499 (VH-499), a new HIV-1 capsid inhibitor|P.l Benn|Oral Abstract 153
11 March 2025
10:21-10:30 PT|
|VH3810109 (N6LS) efficacy and safety in adults who are virologically suppressed: The EMBRACE study|B. Taiwo|Oral Abstract 203
12 March 2025
12:39-12:46 PT|
|Pre-clinical evaluation of effector function-enhanced variants of N6 bnAb|D. Wensel|Poster 547|
|Fostemsavir|
|Temsavir treatment improves the recognition of HIV-1 infected cells by broadly neutralizing antibodies (bnAbs)|H. Qi|Poster 507|
|Characteristics and treatment outcomes of people with HIV prescribed fostemsavir in the trio cohort|M. Ramgopal|Poster 699|
|Dolutegravir|
|Dolutegravir Does Not Reduce Levonorgestrel or Medroxyprogesterone Acetate Concentrations in WLWH|R. Ryan|Oral Abstract 119
10 March 2025
12:39-12:46 PT|
|PK and safety of chronic dolutegravir administration in neonates exposed to HIV-1 (IMPAACT 2023)|J. Momper|Poster 1047|
|Baseline and emergent resistance profiles in the African paediatric CHAPAS-4 trial|A. Bamford|Poster 123|
|Drug interactions between dolutegravir (DTG) and escalating doses of rifampicin (RIF): DORIS study|Y. Singh|Poster 645|
|Switching to DTG/3TC vs. BIC/FTC/TAF and steatotic liver disease: A sub-study of PASODOBLE Trial|J. Pineda|Poster 764|
|Depression, sleep, and anxiety among pregnant and postpartum women using dolutegravir and efavirenz|D. Wu|Poster 986|
|Changes in body composition in people with HIV switching to DTG/3TC or BIC/TAF/FTC|E. Martinez|Poster 897|
|Effectiveness and inflammatory markers after 144 weeks of switch to DTG/3TC in a randomized trial|E. Blomme|Poster 663|
|Switch to DTG/3TC vs BIC/FTC/TAF (PASO-DOBLE study): Efficacy and Weight Changes by Predefined Subgroups|J. Tiraboschi|Poster 661|
|Impact of art simplification with dolutegravir and lamivudine on the HIV reservoir|Fombellida-Lopez|Poster 664|
|Risk of obesity, cardiometabolic disease and MACE after switch to an integrase inhibitor in REPRIEVE|E. Kileel|Poster 838|
|Risk of incident hypertension with common antiretroviral agent combinations in the OPERA cohort|G. Pierone Jr|Poster 823|
|General HIV|
|Brain volume normalization after 96 weeks of ART started during acute HIV infection|R. Paul|Oral Abstract 167
12 March 2025
10:00 AM PT|
|People with HIV exhibit structural brain changes following infection with SARS-Cov-2|J. Bolzenius|Oral Abstract 174
12 March 2025
10:00 AM PT|
|Frailty is associated with higher MACE incidence but does not appear to modify pitavastatin effects|K. Erlandson|Oral Abstract 179
12 March 2025
10:00 AM PT|
|Plaque, inflammation, subclinical myocardial injury and MACE in the REPRIEVE mechanistic substudy|S. Grinspoon|Oral Abstract 178
12 March 2025
10:00 AM PT|
|Cancer incidence in women with HIV in Europe and Australia: a combined D:A:D and RESPOND cohort analysis|W. M. Han|Poster 803|
|Statin effect heterogeneity on plaque volume & composition in the REPRIEVE mechanistic substudy|B. Foldyna|Poster 850|
|No evidence of a detrimental effect of pitavastatin on neurocognitive function among people with HIV|K. Erlandson|Poster 624|
|Prognostic factors of physical function decline in the PREPARE study|G. Ditzenberger|Poster 881|
|Time-updated win ratio aligns with primary REPRIEVE findings and suggests early pitavastatin benefit|E. Smith|Poster 853|
|Determinants of steatotic liver disease among people with HIV in Europe and Australia|C. Riebensahm|Poster 762|
|Hospitalization incidence among young children living with HIV in the Western Cape, South Africa|K. Anderson|Poster 1051|
|People with HIV at high cardiovascular risk were undertreated with statins|S. Esser|Poster 851|
|Increasing methamphetamine use and group sex observed in MSM with acute HIV infection in Bangkok|P. Chan|Poster 1144|
|Heart failure risk and events in people with HIV in the REPRIEVE trial|M. Watanabe|Poster 818|
|Cognitive trajectories 1 year before and after COVID-19 in an AHI cohort|F. Ocampo|Poster 926|
|Immune and virologic trajectories 1.5 years before and after COVID-19 in an early-treated HIV cohort|F. Ocampo|Poster 931|
|ART exposure and accelerated aging in PLHIV: insights from proteomic and methylation clocks|N. Vadaq|Poster 866|
|CCR5 Expression Is Critical for the Maintenance of HIV Control and Reservoir Size|J. dos Santos|Poster 563|
|Genetic regulation of immune responses to CMV in spontaneous HIV controllers|S. Ruijten|Poster 499|
|Delayed HIV-1 rebound correlates with enhanced CD8 T Cell activation in human trials|R. Thomas|Poster 484|
|Rapid clearance of the inducible HIV-1 reservoir after initiation of antiretroviral therapy|M. Puertas|Poster 571|
|Virulent HIV-1B: clinical challenges and proteomic insights|K. Mehta|Poster 358|
|Distinct metabolic perturbations link liver steatosis and incident CVD in lean but not obese PLHIV|N. Vadaq|Poster 760|
|Mitochondrial gene variants in VARS2 influence HIV reservoir and T cells in European HIV controllers|V. Rios Vazquez|Poster 487|
|Multiomics Clustering Reveals Distinct HIV Reservoir Profiles in the 2000HIV Cohort|V. Rios Vazquez|Poster 565|
|Heterogeneity of PD-1 Expression in PLHIV and Its Relationship With Host and Viral-Related Factors|A. Navas|Poster 462|
|Residual HIV Viremia Associates With Reservoir Size, but Not With Immune Activation or Inflammation|T. Otten|Poster 355|
|Neuronal injury in a subset of individuals during acute HIV infection and after immediate treatment|P. Chan|Poster 615|
|Early HIV-1 genetic diversity includes CTL and drug resistance mutations|J. Coffin|Poster 346|
|RV550: the effects of IL-15 super-agonist N-803 with ART in acute infection on T and NK cells|H. Takata|Poster 444|
|RV550: Safety and virological outcomes in blood and lymph nodes of N-803 with ART in acute infection|C. Sacdalan|Poster 512|
|Sex-based differences and genetic regulation of cytokine responses in people living with HIV|S. Ruijten|Poster 371|
|Females with HIV favor interferon responses over inflammation upon TLR7 activation|A. Huber|Poster 470|
|Translational bNAbs|
|Maximizing benefits to participants in analytic treatment interruption studies with bnAb infusions|Y. Li|Poster 508|
|Sensitivity of HIV-1 CRF01_AE Envelopes to Broadly
Neutralizing Antibodies VRC07-523 and PGDM1400|G. Smith|Poster 421|